Thursday, June 8, 2023
In accordance with ACCME Standards for Commercial Support of Continuing Medical Education and the Health Science Center for
Continuing Medical Education Disclosure Policy for CME Activities, faculty members have been asked to disclose any relationship
they may have with commercial supporters of this CME activity or with companies providing drugs, medical equipment, etc, that
may have relevance to the content of their presentations. Such disclosure is intended to provide participants with sufficient
information to evaluate whether any given presentation has been influenced by the faculty's relationship(s) or financial interests
with said companies.
The following faculty have reported receiving something of value from the commercial supporter(s) of this activity or from
a corporate organization whose product(s) may have relevance to the content of their presentations:
Professor, Academic Section of Musculoskeletal Disease, University of Leeds; Clinical Director, Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, England
processing....
The current treatment options in RA include nonsteroidal anti-inflammatory drugs; corticosteroids; synthetic DMARDs, such as methotrexate (MTX), hydroxychloroquine, sulfasalazine, leflunomide, and others; and more recently developed biological DMARDs, which target the specific downstream inflammatory mediators TNF-alpha (infliximab, etanercept, and adalimumab) or IL-1 (anakinra).[8] MTX remains the most widely used agent for initial therapy, although combination therapy has become increasingly common during the last decade, as several clinical trials have demonstrated that combination treatment is superior to monotherapy with DMARDs.[8] At present, none of the available treatments are a cure for RA, and joint damage is largely irreversible. Therefore, the goals of treatment are to produce a remission of symptoms and a full restoration of function with long-term therapy.
